Form 4: Director Gordon Acquires 90,000 Compass Therapeutics Options

Compass Therapeutics Director Carl L. Gordon was granted 90,000 stock options with an exercise price of $5.17, vesting by June 2026 or the next annual meeting.

Summary

• Carl L. Gordon, a Director and 10% Owner of Compass Therapeutics, Inc. (CMPX), acquired 90,000 stock options.
• The options have an exercise price of $5.17 per share.
• The grant date for these options was January 2, 2026, and they expire on January 2, 2036.
• The options vest in full upon the earlier of June 10, 2026, or the date of the Company's next annual meeting of stockholders.
• Gordon is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC and related entities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with the company's long-term performance. The indirect beneficial ownership through OrbiMed is a specific arrangement but doesn't detract from the incentive alignment.

Positives

• The grant of 90,000 stock options to a director aligns management incentives with shareholder interests.
• The options have a 10-year expiration date, providing a long-term incentive.

Negatives

• The exercise price of $5.17 sets a benchmark for future stock performance that must be exceeded for the options to be in-the-money.
• The director's beneficial ownership is indirectly for OrbiMed, not a direct personal investment, which may alter the perception of personal stake.

Risks

• The value of the stock options is entirely dependent on the future stock price of Compass Therapeutics exceeding the exercise price of $5.17.
• The vesting schedule ties the options to future company performance and the timing of the annual meeting, introducing a time-based contingency.

Future Outlook

The grant of stock options with a future vesting date indicates an expectation of continued employment or board service and potential future stock price appreciation, aligning the director's long-term interests with the company's success.

Industry Context

This is a standard compensation practice for directors in the biotechnology or pharmaceutical industry, aiming to align their interests with long-term shareholder value creation. OrbiMed is a significant healthcare investment firm, and its involvement suggests a strategic interest in Compass Therapeutics.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the biotech industry, similar to companies like Moderna or BioNTech, to incentivize long-term performance.
• The 10-year expiration period for options is standard for executive and director compensation plans.
• The vesting schedule, tied to a specific date or the next annual meeting, is also a typical mechanism to ensure continued service and alignment.

Corporate Governance

Related Party Transactions

• Carl L. Gordon, a Director, is a member of OrbiMed Advisors LLC. He is obligated to transfer the economic benefit of the stock options to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will then provide them to OrbiMed Private Investments V-KA, LP. This constitutes a related party transaction due to his affiliation with OrbiMed.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with long-term shareholder value. The ultimate beneficiary being OrbiMed, a significant investor, reinforces institutional commitment.

Next Steps

• The stock options will vest upon the earlier of June 10, 2026, or the date of the next annual meeting of stockholders.
• Carl L. Gordon is obligated to transfer the economic benefit of these options to OrbiMed Advisors and related entities.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. While it indicates continued alignment of interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard governance and compensation event.

Keywords

Compass Therapeutics, CMPX, Stock Options, Form 4, Insider Trading, Director Compensation, Equity Grant, OrbiMed Advisors